Clinical Trial Update: Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

A confirmatory Phase II study evaluating blinatumomab (MT103) in patients with minimal residual disease in B-cell acute lymphoblastic leukemia has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen Research (Munich) GmbH | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-02-12